Kondo Keiichi 近藤慶一

… Alternative Names

KONDO Keiichi 近藤慶一

近藤慶一コンドウケイイチ

Less

Researcher Number	80363836
Other IDs
Affiliation (Current)	2025: 横浜市立大学, 医学研究科, 客員准教授
Affiliation (based on the past Project Information) *help	2021 – 2023: 横浜市立大学, 医学研究科, 客員准教授 2015 – 2021: 横浜市立大学, 附属病院, 准教授 2013: 横浜市立大学, 市民総合医療センター, 准教授 2008 – 2011: Yokohama City University, 市民総合医療センター, 准教授 2007: Yokohama City University, 附属市民総合医療センター, 准教授 2006: 横浜市立大学, 大学病院, 準教授 2005: 横浜市立大学, 市民総合医療センター病院, 準教授
Review Section/Research Field	Principal Investigator Urology / Basic Section 56030:Urology-related Except Principal Investigator Basic Section 56030:Urology-related / Urology
Keywords	Principal Investigator 腎細胞癌 / HIF / 低酸素環境 / 腫瘍内微小環境 / 淡明細胞型腎癌 / 腫瘍内不均一性 / 癌幹細胞 / Microemvironment / Microenvironment / Single cell … More / Renal cell carcinoma / HIF1α / HIFαサブタイプ / AKTサブタイプ / AKT3 / HIFα / AKT / 治療感受性 / 結合蛋白 / 悪性腫瘍 / 腫瘍学 / 環境応答 / 低酸素 / 腎臓 / 癌 … More Except Principal Investigator 腎癌 / 血液マーカー / 免疫チェックポイント阻害剤 / FDG PET/CT / 腎細胞癌 / 単一細胞トランスクリプトーム解析 / 治療標的 / 診断マーカー / 稀少発症 / 遺伝性 / 血液バイオマーカー / 進行性腎細胞癌 / 腫瘍マーカー / 新規治療 / 抵抗性獲得 / 薬物効果判定 / プロテオミクス解析 / ＦＤＧ　ＰＥＴ／ＣＴ / j腎細胞癌 / バイオマーカー / ブドウ糖集積 / 抵抗性獲得機序 / 分子標的治療薬 / 代謝と癌 / 家族性腫瘍症候群 / エピゲノム / 細胞内輸送 / FLCN/FNIP1/FNIP2複合体 / BHD症候群 / 遺伝性腎癌 / 膜輸送 / 癌と代謝 / FLCN / 腎癌抑制遺伝子 Less

腎癌幹細胞は腫瘍内不均一性を示すか？ー淡明細胞型腎癌の根源的治療法を求めてーPrincipal Investigator
- Principal Investigator
  
  近藤慶一
- Project Period (FY)
  2020 – 2024
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 56030:Urology-related
- Research Institution
  Yokohama City University
Research of biomarker for immunotherapy using PET/CT imaging
- Principal Investigator
  
  NAKAIGAWA Noboru
- Project Period (FY)
  2019 – 2023
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 56030:Urology-related
- Research Institution
  Yokohama City University
Analyses of tumorigenesis and identifications of novel diagnostic marker and therapeutic target in hereditary and rare kidney cancers
- Principal Investigator
  
  YAO Masahiro
- Project Period (FY)
  2019 – 2021
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 56030:Urology-related
- Research Institution
  Yokohama City University
Elucidation of renal tumorigenesis driven by FLCN deficiency
- Principal Investigator
  
  Hasumi Hasashi
- Project Period (FY)
  2016 – 2018
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Urology
- Research Institution
  Yokohama City University
Development of the novel therapy for renal cell carcinoma resistance to molecular targeting therapy using the assessment by FDG PET/CT
- Principal Investigator
  
  Nakaigawa Noboru
- Project Period (FY)
  2016 – 2018
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Urology
- Research Institution
  Yokohama City University
Identification of AKT3-HIF1å pathway as a new therapeutic target for renal cell carcinomaPrincipal Investigator
- Principal Investigator
  
  KONDO Keiichi
- Project Period (FY)
  2013 – 2016
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Urology
- Research Institution
  Yokohama City University
Analysis of the effect for proliferation & therapeutic sensitivity according to specific binding protein for each hypoxia-inducible factor(HIF) 1α & 2αPrincipal Investigator
- Principal Investigator
  
  KONDO Keiichi
- Project Period (FY)
  2009 – 2011
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Urology
- Research Institution
  Yokohama City University
Selection of new target genes to overcome the therapeutic resistance according to hypoxic condition,Principal Investigator
- Principal Investigator
  
  KONDO Keiichi
- Project Period (FY)
  2007 – 2008
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Urology
- Research Institution
  Yokohama City University
HIF2αによるヒト腎細胞癌の増殖機構の解析と新規治療薬の開発Principal Investigator
- Principal Investigator
  
  近藤慶一
- Project Period (FY)
  2005 – 2006
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Urology
- Research Institution
  Yokohama City University

All 2024 2022 2020 2019 2018 2017 2016 2013 2011 2010 2008 2007

All Journal Article Presentation

[Journal Article] MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors2024
- Author(s)
  Nagasaka Hirotaka、Kishida Takeshi、Kouro Taku、Igarashi Yuka、Takebe Shinichi、Yamamoto Shotaro、Kondo Takuya、Koizumi Mitsuyuki、Terao Hideyuki、Suzuki Takahisa、Nakaigawa Noboru、Himuro Hidetomo、Wei Feifei、Sasada Tetsuro
- Journal Title
  
  International Journal of Clinical Oncology
  
  Volume: - Issue: 6 Pages: 832-839
- DOI
  10.1007/s10147-024-02477-4
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K08724, KAKENHI-PROJECT-19K09676, KAKENHI-PROJECT-21H02995
[Journal Article] Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancers2022
- Author(s)
  Jikuya R, Murakami K, Nishiyama A, Kato I, Furuya M, Nakabayashi J, Ramilowski JA, Hamanoue H, Maejima K, Fujita M, Mitome T, Ohtake S, Noguchi G, Kawaura S, Odaka H, Kawahara T, Komeya M, Shinoki R, Ueno D, Ito H, Ito Y, Muraoka K, Hayashi N, Kondo K, et.al.
- Journal Title
  
  iScience
  
  Volume: 25(6) Issue: 6 Pages: 104463-104463
- DOI
  10.1016/j.isci.2022.104463
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-20K09582, KAKENHI-PROJECT-21K19721, KAKENHI-PROJECT-23K24474, KAKENHI-PROJECT-21H02954
[Journal Article] Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report2020
- Author(s)
  Iribe Yasuhiro、Furuya Mitsuko、Shibata Yousuke、Yasui Masato、Funahashi Makoto、Ota Junichi、Iwashita Hiromichi、Nagashima Yoji、Hasumi Hisashi、Hayashi Narihiko、Makiyama Kazuhide、Kondo Keiichi、Tanaka Reiko、Yao Masahiro、Nakaigawa Noboru
- Journal Title
  
  Familial Cancer
  
  Volume: 20 Issue: 1 Pages: 75-80
- DOI
  10.1007/s10689-020-00195-0
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19K09717, KAKENHI-PROJECT-20K07395
[Journal Article] Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab2019
- Author(s)
  Tabei T, Nakaigawa N, Kaneta T, Ikeda I, Kondo K, Makiyama K, Hasumi H, Hayashi N, Kawahara T, Izumi K, Osaka K, Muraoka K, Teranishi JI, Miyoshi Y, Yumura Y, Uemura H, Kobayashi K, Inoue T, Yao M.
- Journal Title
  
  BMC Cancer
  
  Volume: 19 Issue: 1 Pages: 298-298
- DOI
  10.1186/s12885-019-5510-y
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-16K11021, KAKENHI-PROJECT-19K09676, KAKENHI-PROJECT-19K09694
[Journal Article] FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.2018
- Author(s)
  Nakaigawa N, Kondo K, Kaneta T, Tateishi U, Minamimoto R, Namura K, Ueno D, Kobayashi K, Kishida T, Ikeda I, Hasumi H, Makiyama K, Hayashi N, Osaka K, Muraoka K, Izumi K, Kawahara T, Teranishi JI, Miyoshi Y, Yumura Y, Uemura H, Inoue T, Yao M.
- Journal Title
  
  Cancer Chemother Pharmacol.
  
  Volume: 81 Issue: 4 Pages: 739-744
- DOI
  10.1007/s00280-018-3542-7
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-16K11021, KAKENHI-PROJECT-16K11020
[Journal Article] 3. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.2017
- Author(s)
  Ito H, Kondo K, Kawahara T, Kaneta T, Tateishi U, Ueno D, Namura K, Kobayashi K, Miyoshi Y, Yumura Y, Makiyama K, Hayashi N, Hasumi H, Osaka K, Yokomizo Y, Teranishi JI, Hattori Y, Inoue T, Uemura H, Yao M, Nakaigawa N.
- Journal Title
  
  Cancer Chemother Pharmacol
  
  Volume: ７９ Issue: 5 Pages: 855-861
- DOI
  10.1007/s00280-017-3275-z
- Peer Reviewed / Acknowledgement Compliant / Open Access
- Data Source
  KAKENHI-PROJECT-16K11021, KAKENHI-PROJECT-15K09885
[Journal Article] H255Y and K508R missense mutations in tumour suppressor folliculin (FLCN) promote kidney cell proliferation.2017
- Author(s)
  Hasumi H, Hasumi Y, Baba M, Nishi H, Furuya M, Vocke CD, Lang M, Irie N, Esumi C, Merino MJ, Kawahara T, Isono Y, Makiyama K, Warner AC, Haines DC, Wei MH, Zbar B, Hagenau H, Feigenbaum L, Kondo K, Nakaigawa N, Yao M, Metwalli AR, Marston Linehan W, Schmidt LS
- Journal Title
  
  Human Molecular Genetics
  
  Volume: 26 Pages: 354-366
- DOI
  10.1093/hmg/ddw392
- Peer Reviewed / Acknowledgement Compliant / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15K14370, KAKENHI-PROJECT-15K10600, KAKENHI-PROJECT-16K11020, KAKENHI-PROJECT-17K08745, KAKENHI-PROJECT-15H04975
[Journal Article] The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.2017
- Author(s)
  Nakaigawa N, Kondo K, Ueno D, Namura K, Makiyama K, Kobayashi K, Shioi K, Ikeda I, Kishida T, Kaneta T, Minamimoto R, Tateishi U, Inoue T, Yao M.
- Journal Title
  
  BMC Cancer.
  
  Volume: １７ Issue: 1 Pages: 39-39
- DOI
  10.1186/s12885-016-3044-0
- Peer Reviewed / Acknowledgement Compliant / Open Access
- Data Source
  KAKENHI-PROJECT-16K11021, KAKENHI-PROJECT-15K09885
[Journal Article] FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma.2016
- Author(s)
  Nakaigawa N, Kondo K, Tateishi U, Minamimoto R, Kaneta T, Namura K, Ueno D, Kobayashi K, Kishida T, Ikeda I, Hasumi H, Makiyama K, Kubota Y, Inoue T, Yao M.
- Journal Title
  
  BMC Cancer
  
  Volume: 16 Issue: 1 Pages: 67-67
- DOI
  10.1186/s12885-016-2097-4
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-25462495, KAKENHI-PROJECT-25462494, KAKENHI-PROJECT-15K09885
[Journal Article] Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases.2016
- Author(s)
  Miyoshi Y, Yoneyama S, Kawahara T, Hattori Y, Teranishi J, Kondo K, Moriyama M, Takebayashi S, Yokomizo Y, Yao M, Uemura H, Noguchi K.
- Journal Title
  
  BMC Cancer
  
  Volume: 16 Issue: 1 Pages: 128-128
- DOI
  10.1186/s12885-016-2176-6
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-25462495, KAKENHI-PROJECT-25462493
[Journal Article] Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer.2016
- Author(s)
  Uemura K, Miyoshi Y, Kawahara T, Yoneyama S, Hattori Y, Teranishi J, Kondo K, Moriyama M, Takebayashi S, Yokomizo Y, Yao M, Uemura H, Noguchi K.
- Journal Title
  
  BMC Cancer
  
  Volume: 16 Issue: 1 Pages: 109-109
- DOI
  10.1186/s12885-016-2160-1
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-25462495, KAKENHI-PROJECT-25462493
[Journal Article] Tumor suppressive function of PTPN23 in testicular germ cell tumors is lost upon overexpression of miR-142-3p2013
- Author(s)
  Kiyoko Tanaka
- Journal Title
  
  Journal of Biological Chemistry
  
  Volume: - Issue: 33 Pages: 23990-23999
- DOI
  10.1074/jbc.m113.478891
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23592356, KAKENHI-PROJECT-24591415, KAKENHI-PROJECT-25462495
[Journal Article] Expression of Aquaporin 1 in Primary Renal Tumors : A Prognostic Indicator for Clear-Cell Renal Cell Carcinoma.2008
- Author(s)
  Huang Y, Murakami T, Sano F, Kondo K, Nakaigawa N, Kishida T, Kubota Y, Nagashima Y, Yao M.
- Journal Title
  
  Eur Urol.
- Data Source
  KAKENHI-PROJECT-19591863
[Journal Article] A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma2008
- Author(s)
  Yao M, Huang Y, Shioi K, Hattori K, Murakami T, Sano F, Baba M, Kondo K, Nakaigawa N, Kishida T, Nagashima Y, Yamada-Okabe H, Kubota Y.
- Journal Title
  
  Int J Cancer. 123(5)
  
  Pages: 1126-32
- Data Source
  KAKENHI-PROJECT-19591863
[Journal Article] A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma.2008
- Author(s)
  Huang Y, Murakami T, Sano F, Kondo K, et. al
- Journal Title
  
  International Journal of Cancer 123(5)
  
  Pages: 1126-1132
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19591863
[Journal Article] Identification and characterization of Birt-Hogg-Dube associated renal carcinoma.2007
- Author(s)
  Murakami T, Sano F, Huang Y, Komiya A, Baba M, Osada Y, Nagashima Y, Kondo K, Nakaigawa N, Miura T, Kubota Y, Yao M, Kishida T.
- Journal Title
  
  J Pathol. 211(5)
  
  Pages: 524-31
- Data Source
  KAKENHI-PROJECT-19591863
[Presentation] TFE3再構成腎細胞癌32例の臨床病理学的解析 (Clinicopathological Analyses of 32 Cases of TFE3-rearranged Renal Cell Carcinomas)2019
- Author(s)
  古屋充子, 馬場理也, 加藤生真, 矢尾正祐, 近藤恒徳, 長嶋洋治
- Organizer
  第78回日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-19K09717
[Presentation] 遺伝性平滑筋腫症および腎細胞癌症候群関連腎細胞癌に対しニボルマブ・イピリムマブ併用療法が奏功した一例2019
- Author(s)
  入部康弘, 中井川昇, 古屋充子, 長嶋洋治, 松元加奈, 中島健寛, 荒木あずみ, 伊藤悠亮, 蓮見壽史, 柴田洋佑, 太田純一, 岩下広道, 林成彦, 槙山和秀, 近藤慶一, 矢尾正祐
- Organizer
  第50回腎癌研究会
- Data Source
  KAKENHI-PROJECT-19K09717
[Presentation] FDG PET/CT to predict short-term outcome in clear cell renal carcinoma treated with nivolumab.2019
- Author(s)
  Nakaigawa N, Tabei T, Kondo K, Kaneta T, Kobayashi K, Ikeda I, Inoue T, Yao M.
- Organizer
  American Society of Clinical Oncology Annual meeting
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K11021
[Presentation] Japan multicenter prospective study: FDG PET/CT in the assessment of advanced renal cell carcinoma treated with sorafenib2018
- Author(s)
  Nakaigawa N, Tateishi U, Kato T, Kaneta T, Kondo K, Sugimoto M, Yao M, Inoue T, Kakehi Y, Kubota Y
- Organizer
  ASCO GU
- Data Source
  KAKENHI-PROJECT-16K11021
[Presentation] 腎細胞癌におけるHIFαサブタイプとAKTサブタイプの相関性の定量的解析2017
- Author(s)
  近藤　慶一
- Organizer
  第26回泌尿器科分子・細胞研究会
- Place of Presentation
  全労済ソレイユ（大分県大分市）
- Year and Date
  2017-03-11
- Data Source
  KAKENHI-PROJECT-25462495
[Presentation] 腎細胞癌におけるHIFαサブタイプとAKTサブタイプの関連性2016
- Author(s)
  近藤　慶一
- Organizer
  第75回日本癌学会学術総会
- Place of Presentation
  パシフィコ横浜（神奈川県横浜市）
- Year and Date
  2016-10-07
- Data Source
  KAKENHI-PROJECT-25462495
[Presentation] mTOR阻害薬は低酸素及び低栄養状態の細胞にも増殖抑制効果を示す2011
- Author(s)
  近藤慶一
- Organizer
  第70回日本癌学会学術総会
- Place of Presentation
  名古屋
- Year and Date
  2011-10-03
- Data Source
  KAKENHI-PROJECT-21592054
[Presentation] mTOR阻害薬は低酸素及び低栄養状態の細胞にも増殖抑制効果を示す2011
- Author(s)
  近藤慶一
- Organizer
  第70回日本癌学会総会
- Place of Presentation
  名古屋
- Data Source
  KAKENHI-PROJECT-21592054
[Presentation] HIF1α及びHIF2αによる腎細胞癌増殖制御機構におけるmTOR経路の関与2010
- Author(s)
  近藤慶一
- Organizer
  第69回日本癌学会総会
- Place of Presentation
  大阪
- Data Source
  KAKENHI-PROJECT-21592054
[Presentation] HIF pathway and mTOR pathway ; How they influenced each other in RCC growth & progression?2010
- Author(s)
  近藤慶一
- Organizer
  第69回日本癌学会学術総会
- Place of Presentation
  大阪
- Year and Date
  2010-09-24
- Data Source
  KAKENHI-PROJECT-21592054
[Presentation] Effect of binding proteins to Hypoxia-lnducible Factor 1&alpha ; &2&alpha ; on growth of renal cell carcinoma.2008
- Author(s)
  Keiichi Kondo
- Organizer
  第67回日本癌学会学術総会
- Place of Presentation
  名古屋
- Year and Date
  2008-10-28
- Data Source
  KAKENHI-PROJECT-19591863
[Presentation] Effect of binding proteins to Hypoxia-Inducible Factor 1α& 2α on growth of renal cell carcinoma2008
- Author(s)
  Kondo K
- Organizer
  第67回日本癌学会総会
- Place of Presentation
  名古屋
- Data Source
  KAKENHI-PROJECT-19591863
[Presentation] 膀胱癌の抗癌剤感受性におけるHypoxia-Inducible Factor(HIF)の関与2007
- Author(s)
  近藤K
- Organizer
  第45回日本癌治療学会総会
- Place of Presentation
  京都
- Data Source
  KAKENHI-PROJECT-19591863
[Presentation] Role of hypoxia-inducible factor-alpha in chemo sensitivity of bladder cancer2007
- Author(s)
  Kondo K
- Organizer
  第66回日本癌学会総会
- Place of Presentation
  横浜
- Data Source
  KAKENHI-PROJECT-19591863

1. YAO Masahiro (00260787)

# of Collaborated Projects: 4 results

# of Collaborated Products: 9 results
2. Nakaigawa Noboru (00237207)

# of Collaborated Projects: 3 results

# of Collaborated Products: 8 results
3. Hasumi Hasashi (40749876)

# of Collaborated Projects: 2 results

# of Collaborated Products: 2 results
4. 古屋充子 (10361445)

# of Collaborated Projects: 1 results

# of Collaborated Products: 3 results
5. Hirano Hisashi

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
6. Linehan W. Marston

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
7. 馬場理也

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
8. 魏菲菲

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
9. 笹田哲朗

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
10. 田中貴代子

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

Kondo Keiichi 近藤 慶一

KONDO Keiichi 近藤 慶一

近藤 慶一 コンドウ ケイイチ

Research Projects

Research Products

Co-Researchers

腎癌幹細胞は腫瘍内不均一性を示すか？ー淡明細胞型腎癌の根源的治療法を求めてーPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Research of biomarker for immunotherapy using PET/CT imaging

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Analyses of tumorigenesis and identifications of novel diagnostic marker and therapeutic target in hereditary and rare kidney cancers

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Elucidation of renal tumorigenesis driven by FLCN deficiency

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Development of the novel therapy for renal cell carcinoma resistance to molecular targeting therapy using the assessment by FDG PET/CT

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Identification of AKT3-HIF1&#229; pathway as a new therapeutic target for renal cell carcinomaPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Analysis of the effect for proliferation & therapeutic sensitivity according to specific binding protein for each hypoxia-inducible factor(HIF) 1α & 2αPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Selection of new target genes to overcome the therapeutic resistance according to hypoxic condition,Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

HIF2αによるヒト腎細胞癌の増殖機構の解析と新規治療薬の開発Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancers2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab2019

Author(s)

Journal Title

DOI

Data Source

Kondo Keiichi 近藤慶一

KONDO Keiichi 近藤慶一

近藤慶一コンドウケイイチ

Identification of AKT3-HIF1å pathway as a new therapeutic target for renal cell carcinomaPrincipal Investigator